Question 1

What amounts of Cerebrolysin did the published trials use?

Accepted Answer

Every amount below is a figure taken from a named study and given to patients who already carried a diagnosis, under hospital supervision. None of it is offered as a suggestion for anyone else, and each figure should be read together with the population that received it. A 2018 meta-analysis of nine stroke trials reports that patients were treated with 30-50 ml once daily for 10-21 days, starting within 72 hours of the stroke. A 24-week Alzheimer's trial compared three amounts, 10, 30 or 60 ml for 12 weeks, against placebo. The CLINCH trial in bleeding strokes set 50 mL daily for 14 days, given into a vein. The unit matters more than it first appears. These are millilitres of a ready-made solution rather than milligrams of a single peptide, so the figures describe how much liquid went into the infusion, not how much of any particular ingredient a patient actually received.

Question 2

Is there a recommended dosing schedule for Cerebrolysin?

Accepted Answer

A manufacturer's label is not among the documents behind this page, so we cannot report one. The closest thing is a professional guideline, and its scope is narrow. In 2021, two European bodies for neurology and rehabilitation issued a joint guideline. It recommended Cerebrolysin at 30 ml/day, intravenous, minimum 10 days, for early rehabilitation after acute ischaemic stroke. When the C-REGS2 registry recorded what doctors gave in routine practice for moderate stroke, the median was 30 ml for a median of 10 days. That guideline is advice from specialists to other specialists. It covers hospital patients in the first days after a stroke, given alongside rehabilitation. It says nothing about dementia, brain injury, or anyone who has not had a stroke. The registry figure, for its part, records what doctors did rather than a test of what works best.

Question 3

Where is Cerebrolysin injected?

Accepted Answer

Into a vein, in nearly every adult study, and usually diluted first into a larger bag of fluid and given as a drip. A 1994 Alzheimer's trial gave 30 ml in 100 ml physiological saline i.v., meaning diluted in salt water and infused into a vein. A 1997 study in painful diabetic nerve damage diluted 20 ml in 500 ml Ringer, a standard drip fluid. The exception is a Russian-language trial in young children, which gave it by injection into muscle every other day. Dilution into an infusion bag is part of the published method, not an incidental detail. A trial that infused a diluted solution over time and a single rapid injection of the same volume are different clinical procedures, and the adult studies behind this page describe the first.

Question 4

How often was it given, and for how long?

Accepted Answer

Daily, in defined courses, almost without exception across the published trials. What varied between studies was whether weekends were skipped, how many weeks the course continued, and whether the frequency was lowered partway through. A 2000 Korean Alzheimer's trial gave 30 mL in 100 mL physiologic saline IV once a day from Monday to Friday for 4 weeks. The CARS stroke trial gave 30 mL a day, once daily for 21 days, starting 24 to 72 hours after the stroke. A motor neurone disease trial gave 10 mL once daily, five days a week for the first month, then three days a week for the next two months. A 1991 trial in a Soviet medical journal divided a daily 15 ml into 10 ml in the morning and 5 ml in the evening, continued for 28 days in patients with mild vascular dementia. Courses of two to four weeks dominate the published record. The motor neurone disease trial, lasting three months with reduced frequency after the first month, is the longest continuous schedule among these studies. Intermittent annual courses, described further down, extended total exposure in other protocols without lengthening any individual course, which is an important distinction when comparing durations across conditions.

Question 5

What did the stroke trials give?

Accepted Answer

Stroke has the largest number of trials, and their protocols cluster tightly around 30 mL daily for 10 to 21 days, nearly always started within the first three days after onset. A 2017 placebo-controlled trial randomised 60 patients to 30 ml/day or placebo for 10 consecutive days, starting in the first 24-48 hours after stroke. The CEREHETIS study ran 30 mL/day over 14 days alongside the clot-busting drug alteplase. A smaller Russian trial tested the higher figure of 50 ml in 47 patients admitted within the first 12 hours. Timing is part of the protocol here, not an afterthought. Each of these trials started within hours or a few days of the stroke, and an amount given at that point, on a hospital ward, describes a different intervention from an identical volume given weeks or months later.

Question 6

What did the brain-injury trials give?

Accepted Answer

Brain-injury protocols tend to begin with a higher daily volume and then step down to smaller maintenance cycles over the following weeks. The two CAPTAIN trials gave 50 mL a day for ten days, followed by two additional cycles of 10 mL a day for 10 days each. A similar step-down appears in a retrospective study of severe injury, where 42 patients received 30 ml/day for 14 days and then 10 ml/day for another 14 days. A 2026 Thai cohort in moderate injury used 30 mL/day intravenously for 10 days. The step-down pattern, a high early course followed by smaller cycles, is a design choice that the trial teams made. None of these studies compared it against a constant schedule, so its presence in several protocols is not evidence that stepping down works better than keeping the amount level.

Question 7

What did the dementia trials give?

Accepted Answer

Dementia trials used lower or similar daily amounts, five days a week, and some repeated the course over years. A 2015 meta-analysis included only trials of 30 ml/day in mild-to-moderate Alzheimer's disease. A vascular dementia pilot compared 10 or 30 ml against saline, given 5 days/week for 4 weeks. A completed phase 4 trial registered in vascular dementia tested 20 ml. The 30 ml figure in Alzheimer's disease partly reflects which trials were run rather than a finding that 30 ml is the right amount; the meta-analysis selected for it.

Question 8

Did a larger amount do more?

Accepted Answer

Not in a straight line, and the direction depends on what was measured. A 2012 review of the dementia trials found doses of 10 and 30 mL most effective for thinking, while higher doses of up to 60 mL did best on behavioural symptoms. In the vascular dementia pilot, patients' cognition improved significantly at the 10 ml dose, while slowing of the brain's electrical rhythm fell at both 10 and 30 ml. In rats with mild brain injury, 0.8 mL/kg or more improved memory, while 2.5 mL/kg or more was needed before movement and sensation improved too. The human figures come from small groups split three ways, which is a weak basis for ranking amounts. Serious-event rates by amount are a separate question, taken up at the Cerebrolysin safety page.

Question 9

Were children given amounts by body weight?

Accepted Answer

Yes. The paediatric studies set the amount per kilogram of body weight, which none of the adult trials described on this page did. A Russian-language study in newborns with perinatal brain damage used 0,1 ml per 1 kg of body mass, as 10 injections every other day. A 2021 review of infants with oxygen-starvation brain injury at birth reports injections of 0.1 ml/kg of body weight twice per week. The trial in children with a speech disorder used 0.1 ml/kg daily on alternate mornings, 30 injections in total over 2 months. These figures belong to infants and toddlers with diagnosed brain injury or a severe speech disorder, given injections by clinical staff. We do not scale them to an adult, and nothing in these studies supports doing so.

Question 10

Were courses repeated, or given in cycles?

Accepted Answer

Often, and repetition was built into several of the more recent protocols. The ESCAS speech trial gave Cerebrolysin or placebo with speech therapy in 10-day cycles over 3 intervals across the first three months after stroke. A 2026 thrombectomy cohort gave 30 mL/day for 21 days straight after the clot was removed, then a second 21-day course at 69-90 days. A 2011 Alzheimer's review argued that benefits lasting months after a course supports its discontinuous administration, meaning courses with gaps between them. An earlier report drawing on a placebo-controlled trial and a later compassionate use programme suggested that repeat treatments may maintain function over the long term. Cycling here means repeated hospital courses separated by weeks or months. It is not the same idea as cycling on and off a self-administered compound, and none of these studies tested the gap length itself.

Question 11

What do the animal amounts mean?

Accepted Answer

They are reported per kilogram of body weight, in different units, and we do not convert any of them to a human figure. A rat study of mild brain injury gave 2.5 ml/kg daily for 28 days, starting 24 hours after the injury. A mouse study of chemotherapy-related memory loss used 44 and 88 mg/kg, injected into the abdominal cavity daily for 28 days. A rat stroke study used doses as low as 0.15 or 0.30 mg/kg. Millilitres per kilogram and milligrams per kilogram are not interchangeable without knowing the strength of the solution, and none of these papers gives it in its abstract. Scaling from a rodent to a person is not validated for this compound, and an animal figure carried across is a guess with a number attached.

Question 12

What is in a millilitre of Cerebrolysin?

Accepted Answer

The trial abstracts almost never state a concentration, which is part of the reason the clinical dosing literature is written entirely in volume. The only strength among these sources is printed on a recalled US vial, labelled CEREBROLYSIN, 107.5 MG/ML in a 10 ML vial. A cell study of nerve damage from high blood sugar tested concentrations from 2-40 mg/ml in culture dishes. A label figure from a recalled vial tells you what one batch claimed, not what was actually in it, and it may not match the solution the hospital trials used. Converting trial millilitres into milligrams on the strength of that label would be arithmetic built on an unverified number.

Question 13

Why do the published amounts differ so much?

Accepted Answer

Because the trials behind this page have not settled the question, and several of the reviews say so directly. The 2019 Cochrane review of vascular dementia notes that the included studies tested varying doses and duration. A 2023 brain-injury meta-analysis called for further multi-center studies to optimize dosing and time of administration. A 2023 brain-injury trial ended by saying research is needed to identify the optimal dosages and treatment protocols. So the spread of 10 to 60 mL is not noise around a known best amount. It is the record of a question still open after three decades of trials.

Question 14

Does any of this apply to a vial bought outside a hospital?

Accepted Answer

The trial amounts describe hospital infusions of the maker's solution. A vial from elsewhere is a different object. The 2025 FDA recall covered Cerebrolysin for Injection, all strengths and presentations, from one Florida firm, so the recall covered more than one strength under that name. A 2023 Russian review adds that look-alike biological preparations can be considered comparable only if they match on how the body handles them, on efficacy and on safety. A millilitre figure from a trial assumes the trial's solution. Without a verified strength and a sterile source, the number has nothing to attach to, which is a fact about the vial rather than a judgement about the reader.

Trial	Patients	Daily amount	Schedule
2000 Korean trial	Alzheimer's disease	30 mL in 100 mL saline, into a vein	Monday to Friday for 4 weeks
CARS trial	Stroke	30 mL	Once daily for 21 days, from 24 to 72 hours after the stroke
Motor neurone disease trial	Motor neurone disease	10 mL	Five days a week for the first month, then three days a week for two months
1991 trial	Mild vascular dementia	15 ml (10 ml morning, 5 ml evening)	28 days

Cerebrolysin protocols in the published literature